Grey’s Anatomy’s Chandra Wilson Opens Up About Her Daughter’s … – PEOPLE.com

As Dr. Miranda Bailey on ABCs Greys Anatomy, Chandra Wilson is used to solving medical mysteries. But when her daughter suddenly came face to face withher own rare disorder, the actress fell straight into detective mode.

After a casual outing with friendswhen she was 16 years old, Sarina McFarlane thought she was fighting a bad case of food poisoning. However, after repetitive attacks of nausea and vomiting, both daughter and motherknew it was something more serious.

She would get these terrible bouts of vomiting and stabbing abdominal pains, Wilson, 47, exclusively tells PEOPLE in this weeks issue. I thought, This was crazy. Something was wrong with my daughter, and nobody could tell me what it was.

For Wilson, watching her daughters struggle nearly got to the point ofunbearable.

I found myself tracking what foods she was eating, where we were, tracking all this information myself, she says. Each hospital visit, I would put the info into a binder. By month eight, I was walking around with this gigantic binder.

After 10frustrating months of unanswered questions and endless hospital visits due to dehydration, McFarlanewas finally diagnosed with mitochondrial dysfunction (severe depletion of the bodys cellular energy supply) andcyclic vomiting syndrome(CVS), a rare disorder that presents with random attacks of committing, nausea, and extreme exhaustion, in 2010.

Now, 23, McFarlane admits she was scared, frustrated and depressed during the months leading to her diagnosis.

People in high school thought I was throwing up because I was trying to lose weight, she says.

The episodes tend to be abrupt, coming at different frequencies, McFarlanes physician, Dr. Richard Boles, the medical director for Courtagen Life Sciences, says. Dueto the symptomslack of diversity, its extremely hard to diagnose.

Theres really no objective criteria to back it up, he says. And, though experts have not found a cure, Boles stresses that it can be controlled with the right medication, vitamins and healthy lifestyle.

As McFarlane made a transition from adolescent care (where she maintained the same group of doctors and nurses) to adult care, her troubles seemed to only get worse.

If you go to the hospital two, three or four times, they think youre a druggie, she says.

You have to go through the process of being believed again, adds Wilson.

Now McFarlane, whos studying screenwriting at Cal State Northridge, and her momtry to remain upbeat.

I could be sad about it, says McFarlane, but its going to come back anyway.

Greys Anatomy airs Thursdays (8 p.m. ET) on ABC.

Excerpt from:
Grey's Anatomy's Chandra Wilson Opens Up About Her Daughter's ... - PEOPLE.com

Grey’s Anatomy’s Jessica Capshaw on Arizona/Eliza’s First Big Challenge, Plus: a ‘Great Chance’ of a Callie Return – TVLine

As weird as it sounds, Greys Anatomy docs Arizona and Eliza may soon miss the bygone days when they had to keep their romance on the D.L. Now that their colleagues have begun to find out about the new couple, they have to see what happens when they actually have a relationship the sex and the commitment versus no commitment, Jessica Capshaw, who plays Robbins, told TVLine earlier this month at PaleyFest. The question becomes, What are they now?

RELATEDGreys Anatomys Ellen Pompeo on Merediths Next Act (With Nathan?): Im Constantly Fighting for Her

Grey's Anatomy's 20 Greatest CouplesEver

Whats more, theres the little matter of uh, very few Grey Sloan attendings can standArizonas new girlfriend. But shes not a villain, Capshaw is quick to note. Shes just representing a threat to Dr. Webber, who everyone loves. So itll probably become a little more apparent who Eliza is in the scheme of things and what shes about.

RELATEDGreys Anatomys Ellen Pompeo Teases the Ep That Will Make Everybody Cry

Though Sara Ramirezs recent beef with ABC would seem to suggest that well never get to see how Arizonas ex Callie reacts to her successor, Capshaw hasnt given up hope. I feel like nothing is impossible, she says. Theres a great chance that she would come back for something.

What do you think? Would you like to see what Torres makes of Minnick? Hit the comments. (With reporting by Vlada Gelman)

Read more here:
Grey's Anatomy's Jessica Capshaw on Arizona/Eliza's First Big Challenge, Plus: a 'Great Chance' of a Callie Return - TVLine

Grey’s Anatomy Stars Name Their Favorite TV Doctors – Today’s … – TV Guide (blog)

Now Playing The Stars of Grey's Anatomy Reveal Their (Other) Favorite TV Doctors

The staff members at Grey Sloan Memorial Hospital on Grey's Anatomy are part of a long history of fictional doctors on television, from Hawkeye to House. But which of their onscreen predecessors provided "career inspiration" for the stars of Grey's?

We asked the cast, who were on hand at PaleyFest in Los Angeles, to name their favorite TV docs -- and while a few of the usual suspects (ahem, George Clooney's ER pediatrician, Dr. Doug Ross) made the cut, a few of their other choices may surprise you.

And don't be fooled -- while these guys may not be performing actual surgeries, they still have to learn all that real-life medical jargon, which is not an easy task.

Check out the video to see which (fake) MDs Chandra Wilson, Jerrika Hinton, Jason George and more cast members from Grey's Anatomy admire the most -- aside from their own colleagues, of course.

Grey's Anatomy airs Thursdays at 8/7c on ABC.

Link:
Grey's Anatomy Stars Name Their Favorite TV Doctors - Today's ... - TV Guide (blog)

The anatomy of a bodyboard – SurferToday

29 March 2017 | Bodyboarding

Modern bodyboards are advanced wave riding crafts. They are designed and shaped to deliver optimal performances in all types of ocean conditions. All attributes of a bodyboard have been fine-tuned so that each model serves a precise requirement.

Today, a bodyboard is way more than a simple waterproof foam board. There's science, knowledge, and experimentation in it. The most popular bodyboard manufacturers take all variables into consideration before releasing their portfolio.

Understanding how a bodyboard works will help you choose the right model for your weight and height, and level of experience. If you still have doubts, consult the bodyboard size chart.

Bodyboards have several fundamental properties. They are as follows:

The Core

It's the bodyboard's constituent foam material. There are two main types of core: Polyethylene (PE), Polypropylene (PP), and Extruded Polystyrene (EPS). The core gives the overall shape of the board, and play a critical role in wave riding performance.

The Deck

It's the bodyboard's top skin and the material that will cushion the impact of the sport's radical maneuvers. The high-end models come with PE decks, but some manufacturers also use crosslink formula.

The Slick

It's the bodyboard's bottom skin, and it should reduce the drag when the board is in contact with the surface of the water, and provide flexibility. The main types of materials used in the deck are Surlyn and HDPE.

The Channel

Channels are canals located near the tail on the bodyboard's slick. The provide extra grip on the face of the wave.

The Rail

It's the bodyboard's steering wheel and has an impact in control and speed. The two main types of rails are the 60/40 and the 50/50.

The Nose

It's the bodyboard's top and has an impact on the wave riding experience. Narrow noses mean a loose control and higher speed, while a wider nose performs better in big wave conditions.

The Rocker

It's the bodyboard's natural curve. A nearly flat rocker makes the board go faster and is harder to control; a board with too much rocker has a lot of drag, but it can be easier to navigate.

The Wide Point

The area of the bodyboard where the contours change their direction. It defines the overall template and the width distribution of the board. For a loose feel, get a board with a lower wide point; for control and speed pick a model with a higher wide point.

The Thickness

Thinner bodyboards are agile and have increased maneuverability, but they are also less buoyant and fast than thicker models with their extra volume.

The Tail

It's the bodyboard's wheel and provides more or less control and speed depending on their shape. The most common tail designs are the bat tail and the crescent tail.

The Stringer

It's the bodyboard's skeleton and provides control, strength, and stiffness. The tube is generally made of fiberglass and is inserted into the core of the board.

Original post:
The anatomy of a bodyboard - SurferToday

ProMIS Neurosciences announces presentation and expert panel participation at the Neuroscience Biopartnering and … – Yahoo Finance

TSX: PMN

TORONTO, March 28, 2017 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its participation in the 2nd Annual Neuroscience Biopartnering and Investment Forum conference organized by Sachs Associates and held at the New York Academy of Sciences on March 27, 2017.

ProMIS Executive Chairman, Eugene Williams, presented an update and overview on the company's rapid progress and future outlook, and also contributed as a member of the expert panel entitled "Advances in Alzheimer's Disease".

"Following on from the Company's successful fund raise announced in February of this year, ProMIS will focus on progressing the development of its antibody program targeting toxic, prion-like forms of Amyloid beta, a root cause of Alzheimer's. Our lead development product, PMN310, is on track for IND submission at the end of 2018", stated Williams. "Furthermore, there is a substantial body of evidence from prior clinical trials in AD that targeting specifically the toxic, prion-like strains of Amyloid beta, while avoiding targeting of Amyloid beta monomer and plaque, will lead to best in class disease modifying therapy".

The Company overview presented at the meeting is available on the ProMIS Neurosciences website at: http://bit.ly/2na9QPl

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platformsProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:www.promisneurosciences.com

Follow us onTwitter Like us onLinkedIn

Originally posted here:
ProMIS Neurosciences announces presentation and expert panel participation at the Neuroscience Biopartnering and ... - Yahoo Finance

New England Allergy, Asthma & Immunology PC Hosts 23-Nation Delegation of Top Healthcare Officials – PR Newswire (press release)

The delegation was comprised of Secretaries and Assistant Secretaries of Health, Program Directors, CEOs, Program Officers, Medical Officers, and many professors and researchers from:

"We are honored and equally humbled to host a delegation of this caliber at our home institution," said Dr. Thomas F. Johnson, Founder, Owner, and Chief Medical Officer of New England Allergy. "This speaks volumes to our commitment to promote the best health standards and to our full endorsement of a borderless world where every nation serves as a building block in global health initiatives to help prevent and combat disease."

"New England Allergy, Asthma & Immunology is pioneering a global system of collaboration across geographies and across medical disciplines to facilitate knowledge transfer, preventative screening, treatment, and efficient healthcare delivery systems," said George Kassas, CEO of Bireme Systems LLC, the Business Managing firm of New England Allergy. "This distinguished delegation's visit reaffirms New England Allergy's mission to welcome patients from all over the world to receive the very best care from many different medical subspecialties centered from our growing, premier facility."

New England Allergy, Asthma & Immunology P.C. http://www.newenglandallergy.com is located in North Andover, M.A. with offices in Lowell, M.A., Newburyport, M.A., Salem, N.H., Hampstead, N.H., and Hooksett, N.H. To learn more about the services offered by the practice, please visit http://www.newenglandallergy.com.

Media Contact:George Kassas+1508-523-4432George.kassas@newenglandallergy.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-england-allergy-asthma--immunology-pc-hosts-23-nation-delegation-of-top-healthcare-officials-300429806.html

SOURCE New England Allergy, Asthma & Immunology P.C.

Home

Original post:
New England Allergy, Asthma & Immunology PC Hosts 23-Nation Delegation of Top Healthcare Officials - PR Newswire (press release)

The new S-Town podcast, from the Serial team, is a real-life Southern gothic – Vox

You are now entering Shit Town.

Thats what the S in S-Town stands for, as we learn in the opening moments of one of the years eeriest new podcasts. The just-launched project is the highly anticipated follow-up to 2014s smash hit Serial, and all seven episodes are available to listen to now.

The details of S-Towns premise have been shrouded in mystery for months. The show was first announced in November, but apart from a few tantalizing hints about murders and treasure hunts, its story was kept largely under wraps.

So the podcasts opening revelation that the S-Town title is a smokescreen for a something much blunter is a perfect setup for the various bluffs, double bluffs, and unexpected U-turns to come. Hosted by This American Life producer Brian Reed, S-Town is about the real life of one man whose attempt to make a difference in his small Alabama community has sweeping, unexpectedly far-reaching repercussions.

Reed spent several years investigating the story, which began with an email from a This American Life fan and evolved into a mystery within a mystery. The story ultimately takes many unique turns that are best left unspoiled, but in the opening act, a man named John convinces Reed to travel to Alabama to help him investigate a murder. From there, Reed gets caught up in the somewhat baffling idiosyncrasies of Shit Town and its residents and above all, in the idiosyncrasies of John himself.

S-Town is the work of podcast royalty: The first podcast to launch under Serials spinoff production company Serial Productions, it is executive-produced by Serial co-creator Julie Snyder, and its editorial team includes longtime This American Life host Ira Glass, Serial host Sarah Koenig, and Starlee Kine, creator of the cult podcast hit Mystery Show.

However, despite its blatant positioning as the heir to the Serial throne, S-Town is not quite the true crime podcast you might be expecting. Instead, its an engrossing narrative about the complexities of human behavior. But there are definitely similarities to Serial and other podcasts that deal in real-life intrigue, like the recent controversial Missing Richard Simmons.

Perhaps inevitably, what seems to be a foray into one mystery abruptly veers into a much larger, more somber, and unexpected tale about how the personal is always political, and how change on an individual level can become change on a universal level.

But it really does include a treasure hunt.

S-Town is now streaming on iTunes, apps like Stitcher, and the S-Town website.

Read more:
The new S-Town podcast, from the Serial team, is a real-life Southern gothic - Vox

Large-scale study finds genetic errors associated with brain cancer – Medical News Today

Hundreds of thousands of people in the United States are living with a brain tumor. Gliomas are a particular category of malignant brain tumor that includes glioblastoma - a tumor with a low survival rate. New research uncovers genetic variants associated with an increased risk of glioma.

A new genetic study carried out by a team of international researchers from the United Kingdom, Europe, and the U.S. identifies 13 new genetic errors that correlate with a high risk of glioma. The findings were published in the journal Nature Genetics.

The National Brain Tumor Society estimate that 688,096 U.S. individuals have a brain tumor, and nearly 140,000 of these are malignant.

Brain tumors are quite aggressive and difficult to treat, with an average of only 34.4 percent of the patients surviving 5 years after their initial diagnosis.

Of the different types of brain tumor, glioma is the most common. It describes a type of tumor that grows from the brain's glial cells, which can be found around the neurons, supporting the nerve cells.

Across all brain tumors, gliomas account for approximately 27 percent and are estimated to cause 13,000 yearly cancer deaths in the U.S., according to research quoted in the new study. Gliomas are usually divided into glioblastomas (GBMs) and non-GBM tumors. Patients diagnosed with GBMs have a survival rate as low as 5 percent.

The authors of the new study note that little is known about the environmental factors that contribute to the risk of being diagnosed with glioma. The researchers set out to examine the genetic background for glioma risk.

The team conducted two new genomic studies and added their findings to that of previously existing studies. The result was a meta-analysis of almost 12,500 people with glioma and more than 18,000 healthy, glioma-free controls.

Overall, the scientists identified 13 new genetic variants that raised the risk of glioma: five new loci were identified for GBM, and eight for non-GBM tumors. The study shows that these genetic errors impact various cell functions, including the genesis and division of neurons, cell cycle regulation, DNA repair, and the production of some proteins.

Additionally, the scientists examined how different genetic strands affect a person's chances of developing GBM and non-GBM tumors.

For instance, they found that the expression of the HEATR3 gene increases the risk of GBM by 18 percent, but it has a much lower impact on non-GBM risk.

Study co-leader Richard Houlston, professor of molecular and population genetics at the Institute of Cancer Research in London in the U.K., comments on the significance of these findings:

"The changes in the way we think about glioma could be quite fundamental," Prof. Houston explains. "So for example, what we thought of as two related subtypes of the disease turn out to have quite different genetic causes which may require different approaches to treatment."

Apart from the newly discovered genetic errors, the study also confirmed the role of other genes that have been previously identified and correlated with the risk of brain and other types of cancer.

Before the new study, the total number of genetic variants linked to glioma risk was 13. The new research doubles this number.

"It has been exciting to have been involved in such a gigantic study including cases of brain cancer from all over the world. We have uncovered a treasure trove of new information about the genetic causes of glioma brain cancers.

Understanding the genetics of glioma in such detail allows us to start thinking about ways of identifying people at high inherited risk, and will open up a search for new treatments that exploit our new knowledge of the biology of the disease."

Prof. Richard Houlston

Learn how scientists inhibit brain tumor cell growth and how it could pave the way for new treatment.

More here:
Large-scale study finds genetic errors associated with brain cancer - Medical News Today

Veritas Genetics Collaborates with Dr. Steven Narod and Women’s College Hospital to Launch The Screen Project – a … – PR Newswire (press release)

Approximately 1 in 200 Canadians have a BRCA1 or BRCA2 mutation, which are strongly associated with the development of breast, ovarian and prostate cancers. However, genetic testing for these gene mutations in Canada is only offered to, and covered for, people who meet strict eligibility criteria based on several factors including having a strong family history of cancer. "Population-based genetic testing is a new approach for widespread screening in Canada that we hope will change the current genetic testing paradigm," said Dr. Steven Narod, co-principal investigator and the director of the Familial Breast Cancer Research Unit at WCH.

With The Screen Project, all Canadians, age 18 years and older, will have access to BRCA1 and BRCA2 screening for a fee of $165 USD. Once they enroll online, participants will receive a saliva testing kit at home. Veritas will process their returned samples at the company's laboratory, and the results will be reported to the patient within 2 to 4 weeks. Those who test positive for a BRCA mutation will be contacted by the Familial Breast Cancer Research Unit at WCH and will be offered additional clinical guidance. Those who receive a negative or inconclusive result will be notified through a report from Veritas.

"For years, our research team have been advocating for population-based genetic testing for BRCA1 and BRCA2, the two most clinically actionable susceptibility genes for breast and ovarian cancers. However, this has not been possible until now mostly because of the high cost of the test and the difficulties in participant enrollment," explained Dr. Mohammad Akbari, co-principal investigator of the study and director of the Research Molecular Genetics Laboratory at WCH. "We found Veritas to be the best match for The Screen Project given their ability to enroll patients quickly and at the best price possible."

"We now know using family history as the only selection criteria for genetic testing can make us miss up to half of all individuals who would greatly benefit from early access to this information," said Mirza Cifric, co-founder and CEO of Veritas. "This is the first of several population-based initiatives we at Veritas will be rolling out in various countries over the coming months. It's equally important to mention that these screening efforts will be coupled with the appropriate follow-up clinical care. This is why we are so excited to work with Dr. Narod and Dr. Akbari at WCH. We believe this is the model for future cancer screening."

Currently, Veritas' myBRCA products are available through distributors in more than 30 countries. Individuals in the U.S. who are interested in BRCA testing can learn more at veritasgenetics.com/mybrca.

About Veritas GeneticsVeritas Genetics is a global leader in providing accessible genetic screening and interpretation to individuals, physicians, and medical researchers. By removing barriers to genetic screening and whole genome sequencing, Veritas Genetics empowers individuals and doctors to make informed lifestyle decisions that help people live longer, healthier lives. The company was recognized by MIT Technology Review as one of the "50 Smartest Companies" in 2016. Veritas was founded by leaders in genomics from Harvard Medical School and operates globally from its offices in the U.S., Europe and China. Learn more at veritasgenetics.com.

About Women's College HospitalFor more than 100 years Women's College Hospital (WCH) has been developing revolutionary advances in healthcare. Today, WCH is a world leader in the health of women and Canada's leading, academic ambulatory hospital. A champion of equitable access, WCH advocates for the health of all women from diverse cultures and backgrounds and ensures their needs are reflected in the care they receive. It focuses on delivering innovative solutions that address Canada's most pressing issues related to population health, patient experience and system costs. The WCH Institute for Health System Solutions and Virtual Care (WIHV) is developing new, scalable models of care that deliver improved outcomes for patients and sustainable solutions for the health system as a whole.

Women's College Research Institute (WCRI) is tackling some of the greatest health challenges of our time. Its scientists are conducting global research that advances the health of women and improves healthcare options for all, and are then translating those discoveries to provide much-needed improvements in healthcare worldwide. For more information about how WCH and WCRI are transforming patient care, visit http://www.womenscollegehospital.ca and http://www.womensresearch.ca.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/veritas-genetics-collaborates-with-dr-steven-narod-and-womens-college-hospital-to-launch-the-screen-project---a-population-based-brca-screening-initiative-across-canada-300430320.html

SOURCE Veritas Genetics

http://www.veritasgenetics.com

Link:
Veritas Genetics Collaborates with Dr. Steven Narod and Women's College Hospital to Launch The Screen Project - a ... - PR Newswire (press release)

Veritas Genetics to Provide BRCA Testing to Participants in Canadian Breast Cancer Screening Effort – GenomeWeb

NEW YORK (GenomeWeb) Veritas Genetics announced today that it has agreed to provide BRCA testing for men and women who participate in a new initiative called The Screen Project being conducted at Toronto's Women's College Hospital (WCH).

Registering provides access to this and other free content.

Already have an account? .

Read the rest here:
Veritas Genetics to Provide BRCA Testing to Participants in Canadian Breast Cancer Screening Effort - GenomeWeb